The Abluminus DES+ sirolimus-eluting stent (SES) exhibited higher rates of ischemia-driven target-lesion revascularization (ID-TLR) and target-lesion failure (TLF) at 12 months in patients with ...
As the new year begins, the landscape of cardiovascular medicine is undergoing a remarkable transformation, driven by groundbreaking technologies and innovative approaches that promise to ...
As part of its broader strategy to expand specialty participation in value-based care, the Centers for Medicare and Medicaid Services (CMS) has finalized a mandatory five-year Ambulatory Specialty ...
Beta-blocker therapy following myocardial infarction (MI) was the primary focus of a hot line session at ESC Congress 2025. Study investigators presented findings from the REBOOT-CNIC and ...
Chronic consumption of high levels of caffeine a day can lead to an increase in high heart rate and blood pressure that persists after resting from a step test, increasing the risk of cardiovascular ...
Cardiovascular clinicians can bill new or revised codes for PCI, lower extremity revascularization (LER), coronary plaque analysis and other services starting Jan. 1, 2026. The ACC Advocacy team has ...
Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...
Until about 15 years ago, most cardiologists were found in private practices, where the physicians – usually in groups – owned the practice and had privileges for hospital-based services at one or ...
Global death counts due to cardiovascular disease (CVD) increased from 12.4 million in 1990 to 19.8 million in 2022, reflecting global population growth and aging and the contributions from ...
The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization for heart failure (HF) or death from any cause among patients with an increased risk for HF following acute ...
The U.S. Food and Drug Administration has approved on April 2 the Abbott TriClip™, a transcatheter edge-to-edge repair (TEER) system specifically designed for the treatment of tricuspid regurgitation ...
Mavacamten did not significantly improve exercise capacity as assessed by peak oxygen uptake or improve patient-reported health status compared with placebo in patients with symptomatic nonobstructive ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results